Interferon beta-1b

Approved Uses

Interferon beta-1b is a prescription medication used in adults to treat various relapsing forms of multiple sclerosis (MS). These conditions include:

• Relapsing-remitting disease: A form of MS where symptoms flare up (relapse) and then go into periods of remission.
• Active secondary progressive disease: A stage of MS where the disease steadily worsens, but patients still experience occasional relapses.
• Clinically isolated syndrome (CIS): This refers to a patient's first clinical episode of MS-like symptoms. The medication is used when MRI results show features consistent with multiple sclerosis, suggesting a high risk of developing the full disease.

Treatment Goals

The primary goals of treatment with interferon beta-1b are to:

• Decrease the frequency of clinical exacerbations (attacks or relapses).
• Delay the progression of physical disability associated with the disease.

Mechanism of Action

Interferon beta-1b belongs to a class of medications known as immunomodulators. It is a synthetic version of a protein that the body naturally produces to help regulate the immune system and manage inflammation.

In people with multiple sclerosis (MS), the immune system mistakenly attacks the protective coating, called myelin, that surrounds the nerves in the brain and spinal cord. This attack leads to inflammation and nerve damage. While the exact way interferon beta-1b works to treat MS is not fully understood, it is believed to help by:

• Reducing inflammation: It helps lower the inflammatory response that contributes to MS symptoms and flare-ups.
• Regulating the immune system: It interacts with specific receptors on the surface of cells to calm the immune response that targets the nervous system.
• Protecting nerves: By decreasing the frequency and severity of immune attacks, it helps prevent further damage to the myelin coating.

By managing these immune responses, the medication helps reduce the frequency of clinical relapses and may help slow the progression of physical disability associated with the disease.

Common Side Effects

Many people experience flu-like symptoms when starting this medication. These symptoms often decrease over time. Common side effects include:

• Flu-like symptoms, such as fever, chills, sweating, and muscle aches
• Injection site reactions, including redness, pain, swelling, or itching
• Headache
• Weakness or tiredness
• Stomach pain or nausea
• Difficulty sleeping

Serious Side Effects

Contact a healthcare provider immediately if you experience any of the following serious symptoms:

• Signs of liver problems, such as yellowing of the skin or eyes, dark urine, or pain in the upper right stomach area
• New or worsening depression, anxiety, or thoughts of hurting yourself
• Severe skin reactions at the injection site, such as skin breakdown, sores, or drainage
• Signs of heart problems, including shortness of breath or swelling in the ankles or feet
• Easy bruising or bleeding, or signs of infection like a persistent fever
• Seizures
• Allergic reactions, such as hives, swelling of the face or throat, or trouble breathing

Serious Allergic Reactions

Interferon beta-1b can cause severe allergic reactions, including anaphylaxis. This medication is contraindicated in individuals with a known history of hypersensitivity to natural or recombinant interferon beta, albumin, or any other ingredients in the product.

Liver Injury

Severe liver damage, including rare cases of liver failure, has been reported. Healthcare providers typically monitor liver function through blood tests before starting treatment and at regular intervals during therapy. Signs of liver problems may include yellowing of the skin or eyes, dark urine, or abdominal pain.

Depression and Mental Health

There is an increased risk of depression and suicidal thoughts or behaviors in patients taking interferon beta-1b. Monitoring for changes in mood, worsening depression, or thoughts of self-harm is important. Patients with a history of depression may require closer observation.

Heart Conditions

Patients with pre-existing heart disease, such as congestive heart failure, should be monitored closely. While the drug does not have direct heart toxicity, the flu-like symptoms associated with it can strain the cardiovascular system.

Injection Site Reactions

Reactions at the site of injection are common and can range from redness and swelling to more severe issues like skin necrosis (tissue death). Rotating injection sites and using proper technique can help reduce these risks.

Blood Disorders

Interferon beta-1b may cause a decrease in blood cell counts, including white blood cells. Regular blood tests are usually performed to monitor for these changes. Additionally, rare but serious conditions involving blood clots in small blood vessels, known as thrombotic microangiopathy, have been reported.

Seizures

Seizures have occurred in patients using this medication, including those with no prior history of seizure disorders.

Pregnancy

The impact of interferon beta-1b on pregnancy is not entirely clear. While most evidence does not show an increased risk of major birth defects, some studies suggest there may be a higher chance of miscarriage or lower birth weight. Healthcare providers generally advise using this medication during pregnancy only if the potential benefit to the mother outweighs the potential risk to the fetus.

Breastfeeding

It is not known if interferon beta-1b is present in human breast milk. Because of the potential for serious side effects in a nursing infant, patients should discuss with their doctor whether to stop breastfeeding or stop the medication. The decision depends on the importance of the drug to the mother's health.

Planning and Discussion

If you are pregnant, nursing, or planning to become pregnant, consult your healthcare provider. They can provide guidance based on the latest research and your individual medical needs.

Available Forms

Interferon beta-1b is available in the following form:

• Lyophilized powder for injection: This medication comes as a sterile powder in a single-dose vial. It must be reconstituted, or mixed, with a specific liquid diluent before it can be used.

Administration Route

This medication is administered by subcutaneous injection. It is typically supplied in a kit that contains the vial of medication, a prefilled syringe containing the diluent, and the supplies needed for administration.

FDA Approval Status

Interferon beta-1b is FDA-approved for the treatment of relapsing forms of multiple sclerosis (MS) in adults. This approval covers several presentations of the disease, including:

• Clinically isolated syndrome
• Relapsing-remitting disease
• Active secondary progressive disease

The medication is intended to decrease the frequency of clinical relapses and may help delay the accumulation of physical disability.

Safety Communications and Warnings

The FDA monitors interferon beta-1b for serious adverse events through the FDA Adverse Event Reporting System (FAERS). While the drug does not currently carry a boxed warning, the following regulatory safety information is documented in the official labeling:

• Hepatic Injury: The FDA-approved labeling includes warnings regarding the risk of severe liver injury. Healthcare providers are advised to monitor liver function tests regularly during treatment.
• Thrombotic Microangiopathy (TMA): In 2016, the FDA identified a potential signal of serious risk for TMA, a condition involving blood clots in small vessels that can lead to organ damage.
• Glomerulonephritis: A potential signal for kidney inflammation (glomerulonephritis) was also identified by the FDA through adverse event reporting.
• Depression and Suicide: Labeling includes warnings for patients regarding the risk of depression and suicidal ideation, which may be exacerbated by treatment.

Prescription Status

Interferon beta-1b is available only by prescription. It is not classified as a controlled substance. There is currently no Risk Evaluation and Mitigation Strategy (REMS) program required for this medication.

Factors Influencing Cost

The price of interferon beta-1b can be significant, as it is a specialty biologic medication used for the long-term treatment of multiple sclerosis. Several factors determine the final cost to the patient:

• Insurance Coverage: Most private insurance plans and Medicare Part D cover interferon beta-1b, but it is typically placed on a high-cost specialty tier. This often requires patients to pay a percentage of the drug's cost (coinsurance) rather than a flat copayment.
• Brand Selection: This medication is available under brand names such as Betaseron and Extavia. While they are biologically similar, insurance companies may prefer one brand over the other, affecting the out-of-pocket price.
• Specialty Pharmacy Requirements: Interferon beta-1b is usually dispensed through specialty pharmacies rather than standard retail locations. These pharmacies coordinate with insurance providers and may offer different pricing or delivery services.

Financial Assistance and Support

Because of the high cost associated with disease-modifying therapies for multiple sclerosis, manufacturers often provide support services. These may include:

• Co-pay Cards: Programs for patients with commercial insurance that can significantly reduce monthly out-of-pocket costs.
• Patient Assistance Programs: Programs that provide the medication at low or no cost to individuals who are uninsured or meet specific low-income requirements.

Patients are encouraged to contact their insurance provider or the drug manufacturer's support program to determine their specific costs and eligibility for financial aid.